---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-008992"
form_type: "8-K"
ticker: null
cik: "0001564824"
company_name: "Allakos Inc."
filed_at: "2025-01-27T23:59:59+00:00"
generated_at: "2026-05-27T09:14:03.001623+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Allakos discontinues AK006 after Phase 1 CSU failure, cuts 75% of workforce

## Summary
- AK006 Phase 1 CSU study failed: mean UAS7 change -8.2 (AK006) vs -12.4 (placebo); no therapeutic activity.
- Workforce reduction of ~75%; ~15 employees to explore strategic alternatives and wind-down trial.
- Restructuring costs estimated $34M-$38M, majority paid H1 2025; Dec 31, 2024 cash ~$81M; June 30, 2025 cash est. $35M-$40M.
- AK006 was well-tolerated with no serious adverse events, but showed no efficacy versus placebo.

## SEC filing metadata
- accession: 0000950170-25-008992
- form_type: 8-K
- cik: 0001564824
- company_name: Allakos Inc.
- filed_at: 2025-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 2.02, 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1564824/000095017025008992/0000950170-25-008992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1564824/000095017025008992/allk-20250127.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-008992
- JSON: https://secwatch.observer/filing/0000950170-25-008992.json
- Plain text: https://secwatch.observer/filing/0000950170-25-008992.txt

## Key facts
- Restructurings & Charges
  Allakos Inc. announced a restructuring with charges of approximately $34 million to $38 million affecting discontinuation of AK006-related activities across clinical, manufacturing, research and administrative functions (approximately 75%).
  - Type: restructuring
  - Charge: approximately $34 million to $38 million
  - Affected area: discontinuation of AK006-related activities across clinical, manufacturing, research and administrative functions
  - Headcount: approximately 75%
  source text: On January 27, 2025, the Company announced plans to discontinue development of AK006. As part of the corporate restructuring, the Company plans to discontinue AK006-related activities across clinical, manufacturing, research and administrative functions. The Company also plans to reduce its workforce by approximately 75%. The total costs related to discontinuing AK006-related activities and reducing the workforce are estimated to be approximately $34 million to $38 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1564824/000095017025008992/0000950170-25-008992-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.